Skip to main content
SpringerLink
Log in

Management of Advanced Heart Failure: An Overview

  • Chapter
  • First Online:
Ventricular-Assist Devices and Kidney Disease

  • 426 Accesses

Abstract

Advanced heart failure is a prevalent and complex disease with high morbidity and mortality. While there are many causes for heart failure, some of the common ones include ischemia, hypertension, alcohol, and viral infections. Management of this disease involves a multidisciplinary team approach and a myriad of resources. Treatment goals include afterload and preload reduction, improving organ and tissue perfusion, and ameliorating signs and symptoms of heart failure such as dyspnea, fatigue, and edema. Treatment options include, but are not limited to, a multitude of medications including intravenous diuretics and inotropic agents for symptomatic control. Quality of life for patients afflicted with this disease process is poor, requiring frequent hospitalizations. Palliative care is an integral part of the treatment approach and helps alleviate some of the suffering.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–59. https://doi.org/10.1161/CIRCRESHAHA.113.300268.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703–12.

    Article  CAS  PubMed  Google Scholar 

  3. Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovas Dis. 2011;54(2):78–85.

    Article  Google Scholar 

  4. Friedrich EB, Bohm M. Management of end stage heart failure. Heart. 2007;93(5):626–31. https://doi.org/10.1136/hrt.2006.098814.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Abouezzeddine OF, Redfield MM. Who has advanced heart failure? Definition and epidemiology. Congest Heart Fail. 2011;17(4):160–8. https://doi.org/10.1111/j.1751-7133.2011.00246.x.

    Article  PubMed  Google Scholar 

  6. Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12(3):323–30.

    Article  PubMed  Google Scholar 

  7. Ali A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in heart failure patients with preserved left ventricular function. Am Heart J. 2006;151(2):444–50.

    Article  Google Scholar 

  8. Remme WJ. Overview of the relationship between ischemia and congestive heart failure. Clin Cardiol. 2000;23:IV-4–8. https://doi.org/10.1002/clc.4960230703.

    Article  CAS  Google Scholar 

  9. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.

    Article  PubMed  Google Scholar 

  10. Sogol J, Javaheri S, Javaheri A. Sleep Apnea, heart failure, and pulmonary hypertension. Curr Heart Fail Rep. 2013;10(4):315–20.

    Article  Google Scholar 

  11. Leiro MGC, Martin MJP. Management of advanced or refractory heart failure. Rev Esp Cardiol. 2004;57:869–83. Vol. 57, num.09. https://doi.org/10.1016/S1885-5857(06)60652-X.

    Article  Google Scholar 

  12. Rame JE, Dries DL, Drazner MH. The prognostic value of the physical examination in patients with chronic heart failure. CHF. 2003;9(3):170–5.

    PubMed  Google Scholar 

  13. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sounds in patients with heart failure. N Engl J Med. 2001;345(8):574–81. https://doi.org/10.1056/NEJMoa010641.

    Article  PubMed  CAS  Google Scholar 

  14. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287(5):628–40. https://doi.org/10.1001/jama.287.5.628.

    Article  PubMed  Google Scholar 

  15. Stevenson LW. Hemodynamic goals are relevant. Circulation. 2006;113:1020–33.

    Article  PubMed  Google Scholar 

  16. Potluri S, Ventura HO, Mulumudi M. Cardiac troponin levels in heart failure. Cardiol Rev. 2004;12(1):21–5.

    Article  PubMed  Google Scholar 

  17. Shah BN, Greaves K. The cardiorenal syndrome. A review. Int J Nephrol. 2011;2011:920195. https://doi.org/10.4061/2011/920195.

    Article  Google Scholar 

  18. Pokhrel N, Maharjan N, Dhakal B, et al. Cardiorenal syndrome: A literature review. Exp Clin Cardiol. 2008;13(4):165–70.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Makani H, Bangalone S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate- a meta- analysis of randomized trials. J Hypertens. 2011;29(7):1270–80. https://doi.org/10.1097/HJH.0b013e3283472643.

    Article  PubMed  CAS  Google Scholar 

  20. Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to nonischemic cardiomyopathy. JACC Heart Fail. 2013;1(4):308–14.

    Article  PubMed  Google Scholar 

  21. Colucci WS, Fifer MA, Lorell BH, et al. Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience. Am J Med. 1985;78(2B):9–17.

    Article  CAS  PubMed  Google Scholar 

  22. Gibbs CR, Jackson G, GYH L. Non-drug management. BMJ. 2000;320(7231):366–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.

    Article  PubMed  Google Scholar 

  24. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429–35.

    Article  Google Scholar 

  25. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618–26.

    Article  CAS  PubMed  Google Scholar 

  26. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181–8.

    Article  CAS  PubMed  Google Scholar 

  27. Mcmurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077.

    Article  PubMed  CAS  Google Scholar 

  28. Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF trial. Clin Cardiol. 1999;22(Suppl 5):V30–5.

    PubMed  Google Scholar 

  29. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet. 1999;353(9146):9–13.

    Article  Google Scholar 

  30. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–55.

    Article  CAS  PubMed  Google Scholar 

  31. Packer M, Coats AJS, Fowler MB, et al. Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.

    Article  CAS  PubMed  Google Scholar 

  32. Barrese V, Taglialatela M. New advances in beta-blocker therapy in heart failure. Front Physiol. 2013;4:323. https://doi.org/10.3389/fphys.2013.00323.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Gheorghiade M, Colucci WS, Swedberg K. B-Blockers in chronic heart failure. Circulation. 2003;107:1570–5.

    Article  PubMed  Google Scholar 

  34. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57. https://doi.org/10.1056/NEJMoa042934.

    Article  PubMed  CAS  Google Scholar 

  35. Cole RT, Kalogeropoulos AP, Georgiopoulou VV, et al. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation. 2011;123(21):2414–22.

    Article  PubMed  Google Scholar 

  36. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.

    Article  CAS  PubMed  Google Scholar 

  37. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    Article  CAS  PubMed  Google Scholar 

  38. Oh SW, Han SY. Loop diuretics in clinical practice. Electrolyte Blood Press. 2015;13(1):17–21. https://doi.org/10.5049/EBP.2015.13.1.17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. De Bruyne LKM. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003;79(931):268–71. https://doi.org/10.1146/pmj.79.931.268.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805. https://doi.org/10.1056/NEJMoa1005419.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675–83.

    Article  CAS  PubMed  Google Scholar 

  42. Bart BA, Goldsmith ST, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296–301. https://doi.org/10.1056/NEJMoa1210357.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA. 2007;297(12):1319–31.

    Article  CAS  PubMed  Google Scholar 

  44. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(8):773.

    Google Scholar 

  45. Strickberger SA, Conti J, Daoud EG, et al. Patient selection for cardiac resynchronization therapy. Circulation. 2005;111:2146–50.

    Article  PubMed  Google Scholar 

  46. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward?: Part II: chronic inotropic therapy. Circulation. 2003;108:492–7.

    Article  PubMed  Google Scholar 

  47. Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. 2015;16(12):29060–8. https://doi.org/10.3390/ijms161226147.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis of chronic dobutamine or mirinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320–4.

    Article  CAS  PubMed  Google Scholar 

  49. LeMond L, Allen LA. Palliative care and hospice in advanced heart failure. Prog Cardiovasc Dis. 2011;54(2):168–78. https://doi.org/10.1016/j.pcad.2011.03.012.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Advocate Christ Medical Center, Oak Lawn, IL, USA

    Ghulam Murtaza

  2. Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL, USA

    William G. Cotts

Authors
  1. Ghulam Murtaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William G. Cotts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William G. Cotts .

Editor information

Editors and Affiliations

  1. Director, Nephrology, Solid Organ Transplantation and Advanced Heart Failure Therapies, Advocate Christ Medical Center, University of Illinois, Oak Lawn, Illinois, USA

    Chaitanya Desai

  2. Clinical Associate Professor of Medicine University of Illinois, Clinical Director, Heart Transplantation and Mechanical Assistance, Advocate Christ Medical Center, Oak Lawn, Illinois, USA

    William G. Cotts

  3. Clinical Professor of Medicine, Section of Nephrology, University of Illinois at Chicago, College of Medicine, Advocate Christ Medical Center, Oak Lawn, Illinois, USA

    Edgar V. Lerma

  4. Associate Professor of Medicine, Division of Nephrology, Department of Medicine, Penn Presbyterian Medical Cente, Perleman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

    Michael R. Rudnick

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Murtaza, G., Cotts, W.G. (2018). Management of Advanced Heart Failure: An Overview. In: Desai, C., Cotts, W., Lerma, E., Rudnick, M. (eds) Ventricular-Assist Devices and Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-74657-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74657-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74656-2

  • Online ISBN: 978-3-319-74657-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation